Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D., Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 4127.

https://doi.org/10.1182/blood.V122.21.4127.4127

Published: 2013

Journal Articles

Autoantigenic Targets of B-Cell Receptors (BCR) Derived From Chronic Lymphocytic Leukemias Bind to and Induce Proliferation of Leukemic Cells.

Klaus-Dieter Preuss, Gerhard Held, MD, Natalie Fadle, Evi Regitz, Maria Kemele, Stephan Stilgenbauer, MD, Andreas Buehler, MD, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 2884.

https://doi.org/10.1182/blood.V120.21.2884.2884

Published: 2012

Journal Articles

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Michael Hallek, MD, Graeme Fraser, Anne-Sophie Michallet, MD, PhD, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, MD, Matt Kalaycio, MD, Stephan Stilgenbauer, MD, Andreas Buehler, Thomas J. Kipps, MD, PhD, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan, MD

Blood (2012) 120 (21): 3925.

https://doi.org/10.1182/blood.V120.21.3925.3925

Published: 2012

Journal Articles

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Dirk Winkler, MD, Raymonde Busch, Andreas Buehler, MD, Michael K. Wenger, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2011) 118 (21): 2841.

https://doi.org/10.1182/blood.V118.21.2841.2841

Published: 2011

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Sebastian Boettcher, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Andreas Buehler, MD, Dirk Winkler, MD, Michael K. Wenger, MD, Myriam Mendila, MD, Clemens Wendtner, MD, Barbara Eichhorst, MD, Hartmut Döhner, MD, Michael Hallek, MD, Michael Kneba, MD

Blood (2011) 118 (21): 1777.

https://doi.org/10.1182/blood.V118.21.1777.1777

Published: 2011

Journal Articles

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Jennifer Edelmann, MD, Karlheinz Holzmann, PhD, W.M. Michael Kühn, MD, Lars Bullinger, MD, Ina Radtke, MD, PhD, Xiaoping Su, PhD, Jing Ma, Ph.D., Dirk Winkler, MD, Andreas Buehler, Michael Hallek, M.D., James R. Downing, MD, Stephan Stilgenbauer, MD, Hartmut Doehner, MD

Blood (2010) 116 (21): 50.

https://doi.org/10.1182/blood.V116.21.50.50

Published: 2010

Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD

Blood (2010) 116 (21): 918.

https://doi.org/10.1182/blood.V116.21.918.918

Published: 2010

Journal Articles

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Thorsten Zenz, MD, Matthias Volden, Theresa Mast, Karsten Nordhausen, Dirk Winkler, MD, Andrea Schnaiter, MD, Andreas Buehler, MD, Karl-Heinz Heider, PhD, Volker Reichardt, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2460.

https://doi.org/10.1182/blood.V116.21.2460.2460

Published: 2010

Journal Articles

Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.

Dirk Winkler, MD, Christof Schneider, MD, Daniela Nitsch, MD, Kerstin Schulze, Thorsten Zenz, MD, Julia Mohr, Andreas Buehler, MD, Annett Habermann, Manuela Zucknick, Axel Benner, Hartmut Döhner, MD, Stephan Stilgenbauer, MD, Daniel Mertens

Blood (2009) 114 (22): 1255.

https://doi.org/10.1182/blood.V114.22.1255.1255

Published: 2009

NARROW

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Autoantigenic Targets of B-Cell Receptors (BCR) Derived From Chronic Lymphocytic Leukemias Bind to and Induce Proliferation of Leukemic Cells.

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only